Astra Biotech Secures Tens of Millions in Pre-B Funding to Advance Domestic High-End Immunoassay Platform Centered on Neural Biomarkers

VCBeat has learned at the earliest opportunity that,Suzhou ASTRABIO Biotechnology Co., Ltd. (hereinafter referred to as “ASTRABIO”) has completed a Pre-B financing round amounting to tens of millions of yuan. This round was led by Shenzhen Zhengxuan Investment Co., Ltd., with continued participation from existing shareholders BioTrack Capital and Chuangshou Investment, as well as a renowned international industrial investment institution.Following this round of financing, ASTRABIO will prioritize the market deployment of systems for medical diagnostics, health check-ups, and pharmaceutical testing, aiming to establish a premium domestic diagnostic brand. Centered on neurological biomarkers, the company will further refine its screening and diagnostic solutions for blood-based neurological biomarkers, thereby enhancing the core brand value and capabilities of its single-molecule immunoassay technology. Meanwhile, ASTRABIO will officially commence its overseas expansion, achieving the goal of taking its premium Chinese-made brand global.

Neurodegenerative diseases driven by global population aging can no longer be ignored. Led by Alzheimer’s disease, these conditions have imposed substantial physical, psychological, and economic burdens on many families. Effective early screening, diagnosis, and treatment have become critically important.

In recent years, with the rapid advancement of ultra-sensitive detection technologies, blood-based biomarker assays utilizing single-molecule immunoassay techniques have been proven effective for the prediction and diagnosis of Alzheimer’s disease (AD) and have been incorporated into expert consensus guidelines on AD diagnosis and treatment both in China and internationally. Meanwhile, breakthrough targeted therapies addressing the underlying etiology of AD, such as Leqembi^®(Lecanemab) has been approved by the National Medical Products Administration and officially entered the Chinese market for the treatment of mild cognitive impairment and mild dementia due to Alzheimer’s disease, thereby achieving a true end-to-end cycle in the AD field with “available methods for diagnosis and available drugs for treatment.”

The neuroscience diagnostics and treatment market, led by Alzheimer’s disease, is demonstrating vibrant growth potential poised for takeoff.

Neurobiomarkers are present in blood at extremely low concentrations, typically at the pg/mL or even fg/mL level. Conventional immunoassays are limited by their sensitivity, making accurate quantification difficult and hindering widespread clinical application. Single-molecule immunoassay technology, with its ultra-high detection sensitivity, has enabled precise measurement of neurobiomarkers in blood and facilitated their clinical application.

As single-molecule immunoassay technology matures and gains broader market adoption, the development of new technologies will unlock a vast blue-ocean opportunity in the IVD market, valued at tens of billions.

Leveraging its proprietary single-molecule immunoassay platform, ASTRABIO has pioneered the domestic market for neuro-hematological biomarkers. By establishing an efficient “industry-academia-research” translation platform, the company has built a premium technology brand and established academic leadership, thereby advancing the clinical translation and market adoption of novel biomarkers centered on neuroscience. Furthermore, ASTRABIO has forged deep collaborations with multiple leading hospitals in China and published numerous high-impact academic papers.

Leveraging years of technological accumulation and product line integration, the company has established a comprehensive presence in Alzheimer’s disease (AD) screening, health check-ups, and in-depth diagnostics. It offers a full range of commercialized kits covering core AD indicators for market launch, driving the standardization of single-molecule technology in neurological blood biomarkers and establishing high industry barriers for single-molecule immunoassay-based AD blood testing. ASTRABIO’s single-molecule immunoassay products are utilized by leading research institutions and top-tier clinical facilities, underscoring the company’s leadership in the application field of neurological disorders.

As a pioneer, the company remains committed to continuous innovation in the field of single-molecule immunoassays, consistently launching new products and technologies to maintain its first-mover advantage and enhance the core brand value and capabilities of its leading single-molecule immunoassay technology.

ASTRABIO has filed over 40 core patent applications, with more than 20 already granted. It holds China’s first invention patent for single-molecule technology. Its PCT patents have been granted in China, Japan, Canada, and Australia, while applications are concurrently pending in the United States, the European Union, and other countries and regions. The company has established collaborations with multiple international enterprises on detection products for neuro-blood biomarkers based on single-molecule immunoassay technology. In addition to actively advancing its global commercialization strategy, ASTRABIO is intensifying efforts for global product registration, building a global operational system, optimizing global supply chain management, and strengthening cooperation with international research institutions to jointly conduct frontier technological research and application development focused on neuro-blood biomarkers.Promoting ASTRABIO to Become a Global Brand with International Influence。

ASTRABIO, founded in 2019, operates an R&D and production center spanning nearly 8,000 square meters. As a high-tech enterprise dedicated to the industrialization of single-molecule immunoassay technology, the company holds full independent intellectual property rights for its core technologies, successfully filling a gap in China’s frontier development in this field. Guided by its vision to “become a trusted supporter and leader in the life and health sector,” and adhering to its mission of “advancing human health through precise diagnostics and creating an infinite future through technological innovation,” ASTRABIO leverages its core single-molecule immunoassay technology to focus on the research and development and clinical translation of novel biomarkers, poised to drive the next generation of transformative advances in immunoassay technology.